Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Net Income towards Common Stockholders (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Net Income towards Common Stockholders for 5 consecutive years, with -$16.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 2.39% to -$16.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$72.9 million, a 19.28% decrease, with the full-year FY2024 number at -$71.6 million, down 97.58% from a year prior.
  • Net Income towards Common Stockholders was -$16.4 million for Q3 2025 at Werewolf Therapeutics, up from -$18.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q2 2023 to a low of -$102.5 million in Q1 2021.
  • A 5-year average of -$21.8 million and a median of -$16.2 million in 2024 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: soared 85.02% in 2022, then tumbled 260.84% in 2024.
  • Werewolf Therapeutics' Net Income towards Common Stockholders stood at -$17.9 million in 2021, then surged by 33.24% to -$11.9 million in 2022, then increased by 17.28% to -$9.9 million in 2023, then crashed by 105.78% to -$20.3 million in 2024, then grew by 19.38% to -$16.4 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Net Income towards Common Stockholders are -$16.4 million (Q3 2025), -$18.0 million (Q2 2025), and -$18.3 million (Q1 2025).